Wegovy, semaglutide

About Wegovy

Wegovy (semaglutide) is manufactured by Novo Nordisk and was approved by the US FDA in 2021 for chronic weight management in adults. The label was later expanded to adolescents aged twelve and older with obesity, and again in 2024 to include cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight. Wegovy is not approved as a diabetes medication; that indication is held by Ozempic, which contains the same molecule at lower weekly doses. Wegovy is delivered as a once-weekly subcutaneous injection using a pre-filled single-dose pen.

Wegovy is one of the most-requested cross-border medicines in the world. Supply has been constrained in many destination countries through 2024 and into 2025, list prices in the United States are high, and patient demand in the Middle East and South Asia continues to outpace what local pharmacies stock. Reserve Meds coordinates a physician-led named-patient pathway for international patients who want a US-sourced, DSCSA-traceable supply with full serial integrity from the wholesaler to the patient's physician.

How Wegovy works

Semaglutide is a GLP-1 receptor agonist. In plain English, it mimics a natural hormone called glucagon-like peptide one, which the small intestine releases after a meal. That hormone tells the brain you are full, slows how quickly the stomach empties, and signals the pancreas to release insulin when blood sugar rises. By holding GLP-1 receptor activity steady across the full week with a single injection, Wegovy reduces appetite, reduces food preoccupation that many patients describe as "food noise," and supports sustained weight loss when paired with a reduced-calorie diet and increased physical activity.

In the STEP clinical trial program, adults on Wegovy lost roughly fifteen percent of baseline body weight on average over sixty-eight weeks, with around one third of patients losing twenty percent or more. Results vary widely by patient, by dose tolerance, by adherence, and by whether lifestyle changes are made alongside the medication. Weight typically returns when the medication is stopped unless lifestyle changes are sustained, so Wegovy is positioned as a long-term therapy rather than a short course.

FDA indications

• Chronic weight management in adults with a body mass index of thirty or greater, or twenty-seven or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.
• Chronic weight management in adolescents aged twelve and older with an initial body mass index at or above the ninety-fifth percentile for age and sex.
• Reduction of major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight. This indication was added by the FDA in 2024 based on the SELECT trial.

Dosing and route

Wegovy is administered by subcutaneous injection once weekly, on the same day each week, with or without food. The dose is titrated upward over sixteen to twenty weeks to reduce gastrointestinal side effects. The typical schedule is 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, then 1.0 mg for four weeks, then 1.7 mg for four weeks, then 2.4 mg as the maintenance dose. The maintenance dose is what most of the trial weight loss is built on. Patients self-inject into the abdomen, thigh, or upper arm using the pre-filled pen, which clicks once at the start of the injection and again when the dose is fully delivered.

Storage is refrigerated between thirty-six and forty-six degrees Fahrenheit, or two to eight degrees Celsius. Pens can be kept at room temperature up to eighty-six degrees Fahrenheit, or thirty degrees Celsius, for up to twenty-eight days. Reserve Meds ships every Wegovy order under validated cold-chain conditions with continuous temperature monitoring.

Common side effects

The most frequently reported side effects are gastrointestinal and tend to ease as the body adapts to each dose step. They include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, and flatulence. Serious but less common risks include pancreatitis, gallbladder disease, low blood sugar in patients also taking insulin or sulfonylureas, kidney injury related to dehydration from vomiting, and worsening of diabetic retinopathy in patients with type 2 diabetes. Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Discuss side effects with your treating physician promptly. Most patients tolerate Wegovy when the dose is escalated slowly, meals are smaller, and hydration is maintained. A small subset of patients cannot tolerate the maintenance dose and remain on a lower step.

Cross-border named-patient access

Reserve Meds operates a named-patient program for Wegovy. The pathway is built for international patients who have a valid prescription from a treating physician in their home country and want a US-sourced, DSCSA-traceable supply shipped to them on a documented regulatory pathway. We do not stock inventory, we do not ship without a prescription, and we do not operate inside the US prescription market. Every shipment is patient-specific, physician-authorized, and routed through a US specialty wholesaler with full serialization on every unit.

Reserve Meds does not replace the relationship with a treating physician. We coordinate the supply leg, the documentation leg, and the cold-chain leg. The clinical leg, including dose decisions, monitoring, and adverse event management, stays with the patient's physician in the destination country. Reserve Meds is not a pharmacy and does not dispense prescription medications inside the United States.

How Reserve Meds coordinates Wegovy

1. Patient or treating physician submits a named-patient request.
2. Clinical team verifies appropriateness of Wegovy for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific NPP or personal-import documentation is prepared.
5. Wegovy is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy under validated cold-chain conditions, with continuous temperature monitoring end to end.